ChromX Health Co., Ltd., founded in 2021 by Dr. Junqi Wang—a Yale University postdoctoral researcher and University of Michigan Ph.D. holder—is a Guangzhou-based innovator revolutionizing non-invasive diagnostics through breath analysis. As a National High-Tech Enterprise and a core participant in China's Disruptive Technology Innovation Program, the company has developed the world's first chip-based miniaturized gas chromatograph by integrating MEMS, microfluidic, and AI technologies. This breakthrough achieves parts-per-trillion (ppt) sensitivity, surpassing international benchmarks while reducing equipment costs compared to traditional systems.
Certified as a Class II Medical Device in China, ChromX Health's solutions have been deployed in physical examination centers and community healthcare networks. The company is expanding into chronic disease management, with plans to introduce home-based monitoring devices.
To date, ChromX Health has secured nearly 100 million yuan in funding from leading investors such as ZhenFund, Country Garden Ventures, and Fosun. It collaborates with over 30 institutions, including the National Clinical Research Center for Respiratory Diseases, Peking Union Medical College Hospital, and West China Hospital, to advance 30+ clinical trials and to build a global breath metabolomics database.
The brand's "X" symbolizes its commitment to decoding the unknown molecules in human breath, positioning ChromX Health as a global leader in precision diagnostics that is accessible, affordable, and transformative for healthcare ecosystems worldwide.